Effects of N-PEP-12 on Memory Among Older Adults

Int Clin Psychopharmacol. 2005 Mar;20(2):97-100. doi: 10.1097/00004850-200503000-00006.


N-PEP-12 is a derivative of cerebrolysin, a brain-derived neuropeptide compound that has been approved for the treatment of Alzheimer's disease (AD) in more than 30 countries. N-PEP-12 is much less potent than cerebrolysin but it can be administered orally whereas the parent compound must be administered through multiple intravenous infusions. This study was undertaken to determine whether N-PEP-12 is effective in improving memory and other cognitive abilities among healthy older adults who have experienced 'normal' age-related memory loss. Subjects were 54 males and females, aged 50 years and older, who presented both subjective and objective evidence of memory loss since early adulthood. The study was a fully randomized, double-blind comparison of N-PEP-12 and placebo. Cognitive assessments were performed at baseline and following 30 days of treatment. The primary outcome measure was the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) Memory score, with the Syndrom Kurz Test (SKT) test, digit cancellation, digit span, verbal fluency and clinical ratings as secondary outcomes. N-PEP-12 treated subjects performed better than placebo-treated subjects on the ADAS-cog Memory score, the SKT, clinical ratings and some, but not other tests. N-PEP-12 may be an effective treatment for memory loss in healthy older adults.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Amino Acids / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Memory / drug effects*
  • Memory Disorders / drug therapy
  • Memory Disorders / psychology
  • Middle Aged
  • Nootropic Agents / therapeutic use*
  • Treatment Outcome


  • Amino Acids
  • N-PEP-12
  • Nootropic Agents